Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25254340 | 0.89 | RIPK1 (0.43) | RIPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30338765 | 0.89 | RIPK1 (0.43) | RIPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25296027 | 0.89 | RIPK1 (0.43) | RIPK1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL25816830 | 0.87 | RIPK1 (0.43) | RIPK1EGFRKDM4EALDH1A1HPGD | |
| SCHEMBL25816867 | 0.87 | RIPK1 (0.47) | RIPK1EGFRKDM4EALDH1A1HPGD | |
| SCHEMBL30339067 | 0.87 | RIPK1 (0.43) | RIPK1EGFRKDM4EALDH1A1HPGD | |
| SCHEMBL25819780 | 0.86 | RIPK1 (0.42) | RIPK1EGFRKDM4EALDH1A1HPGD | |
| SCHEMBL25819790 | 0.84 | RIPK1 (0.55) | RIPK1NNMT | |
| SCHEMBL25816782 | 0.83 | RIPK1 (0.46) | RIPK1EGFRKDM4EALDH1A1HPGD | |
| SCHEMBL30338650 | 0.83 | RIPK1 (0.42) | RIPK1EGFRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885EGFR 4286/4885KDM4E 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.